NINDS has issued a press release regarding the publication of the NN102 SPRINT-MS study results in the New England Journal of Medicine. The press release quotes NINDS Director Walter J. Kroshetz, MD, saying the NN102 SPRINT-MS findings "provide a glimmer of hope for people with a form of nultiple sclerosis that causes long-term disability but does not have many treatment options."
The results of the NN102 SPRINT-MS have been posted online at the New England Journal of Medicine.
The National Institute of Neurological Disorders and Stroke announced the renewal of the NeuroNEXT Network for an additional five years of funding.
The University of Iowa highlighted NeuroNEXT achievements in two campus publications: Iowa Now provides an overview of the ways the Network is accelerating the clinical trials process, and The Daily Iowan focuses on the ways NeuroNEXT is bringing together clinical sites and coordinating centers to advance neurological trials.
The Clinical Trials Methodology Course (CTMC) has begun their 2018 Webinar Series. These webinars are open to all. The course focues on the desing of early stage clinical trials for investigators focused on neurological illness and injury. The full scheduled may be viewed online: https://siren.network/training/ctmc/ctmc-webinars.
Neuro Central Podcast NC Talks featured an interview with Dr. Robert Fox, PPI of the NN102 SPRINT-MS study. Dr. Fox discussed trial results with the podcasters at the American Academy of Neurlogy's 70th Annual Meeting in Los Angeles, CA.
The American Academy of Neurology (AAN) Annual Meeting will begin April 21 in Los Angeles, CA. The following NeuroNEXT events and presentations will take place:
Network successes and the five-year renewal application were presented at the 2018 Annual Meeting of the American Society for Experimental Neurotherapeutics poster session.
Final results from the NN104 RHAPSODY trial, which were presented at the International Stroke Conference (ISC) 2018 as a closing event, were subsequently featured in ISC's Science News as Featured Science and on the American Stroke Association blog "Blogging Stroke."
Results of the NN104 study were covered in the San Diego Union-Tribune. The article details the development of 3K3A-APC, the study drug, originally developed by The Scripps Research Institute in La Jolla, CA.
The FDA released several guidance documents in February, 2018, three of which fall under the NeuroNEXT umbrella: 
ALS,
In the same issue where the NN101 SMA primary results were published, the Annals of Neurology also published an accompanying editorial.
The NeuroNEXT Network achieved an important milestone with the publication of the primary results from the first completed NeuroNEXT study, NN101 SMA, in the December 2017 issue of Annals of Neurology.
MediciNova, the industry sponsor of NN102 SPRINT-MS, announced the positive top-line results from the trial. The second funded NeuroNEXT trial, a study to evaluate the activity, safety, and tolerability of Ibudilast in patients with Multiple Sclerosis (MS), has very promising results for MS treatment. Results indicate that Ibudilast demonstrated a statistically significant reduction in the rate of progression of whole brain atrophy as compared to placebo.
MediciNova announces the abstract from the NN102 SPRINT-MS study was selected as a platform presentation for late-breaking presentation at the 7th joint ECTRIMS-ACTRIMS meeting. Robert Fox will give the presentation of top line data on October 28, 2017 in Paris.
Chris Coffey and Laurie Gutmann presented at the 2014 NINDS-funded Clinical Trials Methodology Course.
View the poster presented at the 2013 Families of SMA Annual Meeting by the NN101 SMA team.
The August 2013 issue of Annals of Neurology describes how NeuroNEXT can streamline neurological research.
In a January/February 2013 editorial, the president of the Child Neurology Society praises the formation of the NeuroNEXT Network and the possibility for it to rapidly evaluate new treatments for neurological disorders.